Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Common Equity (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Common Equity readings, the most recent being $14.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 50.62% year-over-year to $14.6 million, compared with a TTM value of $14.6 million through Dec 2025, down 50.62%, and an annual FY2025 reading of $14.6 million, down 50.62% over the prior year.
  • Common Equity hit $14.6 million in Q4 2025 for Lisata Therapeutics, down from $17.1 million in the prior quarter.
  • The five-year high for Common Equity was $60.7 million in Q1 2023, with the low at $14.6 million in Q4 2025.
  • Median Common Equity over the past 3 years was $35.7 million (2024), compared with a mean of $36.7 million.
  • The sharpest move saw Common Equity decreased 29.59% in 2024, then plummeted 50.62% in 2025.
  • Year by year, Common Equity stood at $47.9 million in 2023, then crashed by 38.26% to $29.6 million in 2024, then crashed by 50.62% to $14.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $14.6 million, $17.1 million, and $20.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.